Skip to Content
Merck

Key Documents

View All Documentation

T0318

Tranilast

≥98% (HPLC), LTC4 inhibitor, powder

Synonym(s):

2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid, 3,4-DAA, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, Rizaben, SB-252218

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H17NO5
CAS Number:
53902-12-8
Molecular Weight:
327.33
UNSPSC Code:
41106500
PubChem Substance ID:
24278719
NACRES:
NA.77
MDL number:
MFCD00864787
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Tranilast, ≥98% (HPLC), powder

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

mp

166.2-168.2 °C (lit.)

solubility

DMSO: >10 mg/mL, H2O: insoluble

originator

Kissei

storage temp.

2-8°C

SMILES string

COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC

InChI

1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+

InChI key

NZHGWWWHIYHZNX-CSKARUKUSA-N

Gene Information

human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)

Application

The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.

Biochem/physiol Actions

Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro.
Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).

Features and Benefits

This compound was developed by Kissei. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Tranilast

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000506444
0000506444
0000477147
0000417342
0000417343

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells
Harigai R, et al.
Scientific reports, 8(1), 6069-6069 (2018)
Noriaki Minami et al.
Cancer medicine, 6(11), 2635-2645 (2017-10-06)
Therapeutic options for malignant brain tumors are limited, with new drugs being continuously evaluated. Organotypic brain slice culture has been adopted for neuroscience studies as a system that preserves brain architecture, cellular function, and the vascular network. However, the suitability
Natsuko Kageyama-Yahara et al.
FEBS letters, 584(1), 111-118 (2009-11-12)
Mast cell activation by immunoglobulin E (IgE)-mediated stimuli is a central event in the pathogenesis of allergic disorders. The present report shows that treatment with pentagalloylglucose (PGG) resulted in a down-regulation of FcepsilonRI surface expression on mucosal-type murine bone marrow-derived
View All Related Papers